Who Paid My Doc
Mark Dransfield
Critical Care Medicine Birmingham, AL Medical Doctor
NPI 1770526725 CMS profile 1182048
2000 6Th Ave S, Birmingham, AL 35233
General payments
$160,092
Research payments
$3,281
Ownership & investment interest
$0
Research they led as principal investigator
$334,815
Through program year 2025, Mark Dransfield of Birmingham, AL is reported in the CMS Open Payments database as having received $160,092 across 83 general payments and $3,281 in research payments paid to them. Separately, studies naming them as principal investigator received $334,815 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $134 | 1 | |
| 2024 | General | $2,492 | 3 | |
| 2023 | General | $26,215 | 9 | |
| 2021 | General | $4,476 | 3 | |
| 2021 | Research | $3,281 | 1 | |
| 2020 | General | $34,285 | 7 | |
| 2019 | General | $92,490 | 60 |
Beside peers
- Mark Dransfield
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Mark Dransfield were reported at $134. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.
Show as a table
| Year | Mark Dransfield | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $92,490 | $149 | $51–$535 | $163 |
| 2020 | $34,285 | $110 | $30–$325 | $114 |
| 2021 | $4,476 | $125 | $34–$403 | $132 |
| 2022 | $0 | $157 | $49–$582 | $149 |
| 2023 | $26,215 | $162 | $56–$621 | $160 |
| 2024 | $2,492 | $168 | $53–$634 | $164 |
| 2025 | $134 | $189 | $59–$844 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 13 drugsPart D claims
348
Drug cost
$126,487
Branded share of claims
76.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 62 | $61,786 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 17 | $13,068 | |
| Spiriva Handihaler Tiotropium Bromide | Brand | 16 | $12,182 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 21 | $11,638 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 20 | $7,929 | |
| Incruse Ellipta Umeclidinium Bromide | Brand | 12 | $5,899 | |
| Wixela Inhub Fluticasone Propion/Salmeterol | Brand | 15 | $5,126 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 82 | $3,517 | |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | Brand | 11 | $2,774 | |
| Roflumilast | Generic | 13 | $1,091 |
The 10 drugs with the highest cost, of 13 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 6 billing codesPaid by Medicare
$1,890
Medicare patients
18
Services billed
32
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| COPD | 75% | |
| High blood pressure | 67% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
84 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in Alabama
James Wells
Critical Care Medicine · Birmingham, AL
George Solomon
Critical Care Medicine · Birmingham, AL
Tracy Luckhardt
Critical Care Medicine · Birmingham, AL
Keith Wille
Critical Care Medicine · Birmingham, AL
Victor Thannickal
Critical Care Medicine · Birmingham, AL
Samuel McElwee
Critical Care Medicine · Birmingham, AL
Related records
Critical Care Medicine in Alabama
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Alabama
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.